Anixa Biosciences (ANIX) Update Summary Company Overview - Anixa Biosciences was reinvented in 2017 as a biotechnology company focusing on cancer therapies, with a robust pipeline of products currently in clinical trials [5][6] - The company has established partnerships with leading organizations such as the Cleveland Clinic and Moffitt Cancer Center, and receives funding from the U.S. Department of Defense and the National Cancer Institute [6][7] Financial Position - Anixa maintains a strong balance sheet with over two years of cash on hand, allowing for significant clinical milestones without frequent capital raises [8][12] - The company has a clean capital structure with 32 million shares of common stock and no warrants or preferred stock [10][11] Clinical Programs CAR T Therapy for Ovarian Cancer - The CAR T therapy targets terminally ill ovarian cancer patients and is currently in clinical trials at Moffitt Cancer Center [17][19] - The therapy utilizes a unique target, the follicle stimulating hormone receptor (FSHR), which is only found on ovarian cells and tumor blood vessels, allowing for a dual mechanism of action [29][31] - Early results show promising outcomes, with some patients living significantly longer than expected [39][41] - The FDA has approved the possibility of administering a second dose to patients showing initial responses, which is a rare approval for CAR T therapies [41][80] Breast Cancer Vaccine - The breast cancer vaccine aims to treat and prevent breast cancer, particularly targeting triple-negative breast cancer [42][43] - The vaccine is based on the alpha lactalbumin protein, which is produced during lactation and is found in many breast cancer cells [43][44] - Initial Phase I trials have shown strong immune responses and safety, with plans for a Phase II trial to compare the vaccine's effectiveness against standard care [51][55] - The vaccine has the potential to change the paradigm of cancer prevention, aiming for primary prevention in women without a history of cancer [59][60] Market Opportunities - Anixa is addressing large markets, including breast and ovarian cancer, with plans to expand into lung, prostate, and colon cancer [7][20][61] - The company anticipates significant market opportunities if their therapies prove successful, particularly in the context of the breast cancer vaccine [58][61] Strategic Partnerships and Funding - Discussions with potential pharmaceutical partners for both the CAR T therapy and breast cancer vaccine are ongoing, with hopes for fruitful collaborations in the near future [68] - The U.S. Department of Defense has funded the breast cancer vaccine study, recognizing its potential to change cancer treatment landscapes [70][71] Key Milestones and Future Outlook - Upcoming milestones include comprehensive clinical data presentations at the San Antonio Breast Cancer Conference and ongoing updates on patient outcomes for the CAR T therapy [64][66] - The company is optimistic about the potential for partnerships and funding based on the promising early results from their clinical trials [68][86]

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Core Viewpoint - Anixa Biosciences, Inc. is set to host an investor webcast on June 26, 2025, to discuss its business strategy, therapeutic portfolio, market opportunities, and upcoming milestones [1][2]. Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention [4]. - The company is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology [4]. - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer developed with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [4]. - The company partners with renowned research institutions to explore emerging technologies for development and commercialization [4]. Webcast Details - The webcast will feature an introductory presentation by Dr. Amit Kumar, Anixa's Chairman and CEO, followed by a Q&A session for investors [2]. - Interested participants must pre-register to listen to the webcast and ask questions during the live event [3].

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

SAN JOSE, Calif., June 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was featured on Fox News' "Fox & Friends." Both the New York Post and Fox News highlighted the potential of Anixa's vaccine to change the paradigm for breast cancer tr ...

ANIXA BIOSCIENCES INC (ANIX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a chang ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is ANIXA BIOSCIENCES INC (ANIX) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.ANIXA BIOSCIENCES INC is a member of our Medical group, which includes 999 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups an ...

Revenue - No revenue was generated during the three-month and six-month periods ended April 30, 2025 and 2024[84][92] Expenses - Research and development expenses decreased by approximately $324,000 to approximately $1,322,000 in the three months ended April 30, 2025, compared to approximately $1,646,000 in the same period of 2024[87] - General and administrative expenses decreased by approximately $140,000 to approximately $1,681,000 in the three months ended April 30, 2025, from approximately $1,821,000 in the same period of 2024[88] - Research and development expenses for cancer vaccines and CAR-T therapeutics were approximately $1,873,000 and $1,001,000, respectively, during the six months ended April 30, 2025[94] - General and administrative expenses decreased by approximately $566,000 to approximately $3,515,000 in the six months ended April 30, 2025, from approximately $4,081,000 in the same period of 2024[96] Income - Interest income decreased by approximately $96,000 to approximately $190,000 in the three months ended April 30, 2025, from approximately $287,000 in the same period of 2024[89] - Interest income decreased by approximately $243,000 to approximately $363,000 in the six months ended April 30, 2025, from approximately $606,000 in the same period of 2024[97] Assets and Cash Flow - Total current assets decreased by approximately $4,596,000 to approximately $16,766,000 at April 30, 2025, compared to approximately $21,362,000 at October 31, 2024[100] - Cash used in operating activities was approximately $4,407,000 during the six months ended April 30, 2025[101] Net Loss - The net loss attributable to noncontrolling interest decreased by approximately $24,000 to approximately $52,000 in the six months ended April 30, 2025, from approximately $76,000 in the same period of 2024[98] Internal Controls - There was no change in internal control over financial reporting during the three months ended April 30, 2025, that materially affected internal control[117] - The Chief Executive Officer and Chief Financial Officer concluded that disclosure controls and procedures are effective as of the end of the reporting period[116] Compensation Allocation - The company allocates certain internal compensation costs to research and development expenses based on management's estimates of employee time and effort[113]

Anixa Biosciences (ANIX) FY 2025 Conference May 20, 2025 11:00 AM ET Speaker0 Alright. For this session, we'll have a presentation, by Anixa Biosciences. Anixa is a clinical stage immuno oncology company with a pipeline of candidates targeting breast cancer and ovarian cancer. Presenting for the company is Mr. Mike Catalani, President, Chief Operating Officer and Chief Financial Officer of of Adnexa. Mike? Speaker1 Thanks, Yi. Thanks, everybody, for being here. And, for those of you listening, webcast now o ...

SAN JOSE, Calif., April 30, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference, to be held on May 20, 2025, at Nasdaq World Headquarters in New York City.Mike Catelani, President and CFO of Anixa, will deliver a presentation and will be available for one-on-one meetings during the conference.Details ...